At the J.P. Morgan Healthcare Conference 2026, Roche Pharma CEO Teresa Graham outlined the company’s priorities for the coming years: maximising the on-market portfolio to sustain growth through 2028, delivering key launches in 2026, and preparing broad entry into novel disease areas such as Alzheimer’s and obesity through new molecular entities (NMEs).
Roche said it is on track to meet its 2025 financial target, reporting year-to-date sales through September 2025 of CHF 35.6 billion ($44.5 billion), with CHF 18 billion ($22.5 billion) coming from its oncology and haematology franchise. The marketed portfolio continues to expand, with 17 blockbuster drugs contributing to growth.
Oncology and haematology remain core strengths, particularly in breast cancer (Phesgo, Kadcyla, Perjeta, Itovebi), solid tumours (Tecentriq), diffuse large B-cell lymphoma (Polivy, Lunsumio), and haemophilia A (Hemlibra). Roche said it builds and accelerates its pipeline through partnerships and acquisitions, with around 60% of its R&D pipeline and total drug sales involving external collaborations. The company expects to file up to three NMEs in 2026.
A focal point of Roche’s oncology pipeline is giredestrant, a next-generation selective oestrogen receptor degrader (SERD) in Phase III for early and metastatic breast cancer. Giredestrant plus everolimus is in pre-registration with the US Food and Drug Administration, and an European Medicines Agency filing is expected in 2026. Roche said giredestrant has the potential to replace standard endocrine therapy in ER-positive breast cancer and to combine synergistically with PI3K/AKT/mTOR pathway inhibitors.
Giredestrant is supported by a portfolio of small molecules targeting key signalling nodes, including PI3K inhibitor Itovebi, a CDK4/6 inhibitor GDC-4198 aimed at overcoming resistance to CDK4/6 inhibitors, and a brain-penetrant HER2 tyrosine kinase inhibitor ZN-1041. Key Phase III readouts expected in 2026 include giredestrant plus palbociclib in first-line ER+/HER2- metastatic breast cancer (persevERA), Itovebi with fulvestrant in post-CDK inhibitor HR+ metastatic breast cancer (INAVO121), and Itovebi with Phesgo in PIK3CA-mutant HER2+ metastatic breast cancer (INAVO122).
Analyst consensus from GlobalData forecasts giredestrant reaching $1.7 billion in sales by 2031. The oral SERD space is highly competitive: AstraZeneca’s camizestrant is in pre-registration with the FDA and forecast at $1.8 billion in 2031, while palazestrant from Olema Pharmaceuticals is in Phase III and projected at $1.3 billion for the same year. Roche indicated that clinical differentiation and in-house combinations will be key to securing leadership in the HER2-/HR+ segment.
Other regulatory milestones expected in 2026 include a potential US approval for the Lunsumio plus Polivy combination in diffuse large B-cell lymphoma. Notable clinical readouts next year will include Phase III data for the KRAS G12C inhibitor divarasib in non-small cell lung cancer (KRASCENDO 1) and a label expansion for Lunsumio into earlier lines for follicular lymphoma (CELESTIMO).
In haemophilia A, Roche highlighted NXT007, a bispecific antibody targeting coagulation factors IX and X licensed from Chugai Pharmaceutical, as a potential blockbuster. GlobalData’s consensus projects NXT007 sales of $760 million in 2031.
Graham expressed confidence in Roche’s ability to deliver growth through 2028 from its marketed portfolio, upcoming 2026 launches, and anticipated positive Phase III readouts. She also highlighted a pipeline of potential first-in-class and best-in-class medicines across oncology, haematology, immunology, neurology, and ophthalmology, and reiterated Roche’s ambition to be a top-three player in obesity with five NMEs planned for 2026 focusing on continued iteration of the incretin pathway and novel mechanisms of action.
Leave a Reply